• EV-Transferred ACLY Drives TAM Formation in HCC

  2026-08-14

  The Advanced Science study identifies extracellular vesicle transfer of ATP-citrate lyase as a direct metabolic signal that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its CD81-targeted liposomal models establish a causal link between ACLY-driven palmitate production, immune-checkpoint protein stability, tumor progression, and improved anti-PD-1/PD-L1 responses.

• Vorinostat Workflow for Cancer Biology Research

  2026-08-14

  Build a reproducible Vorinostat workflow that connects HDAC target engagement with chromatin remodeling, cell-cycle arrest, and intrinsic apoptosis. The guide also shows how to benchmark responses across lymphoma and neuroblastoma models while avoiding common solvent, timing, and assay-normalization errors.

• Azithromycin and Roxithromycin as Senolytics

  2026-08-13

  Ozsvari et al. used DNA-damage-induced human fibroblast senescence to identify azithromycin and roxithromycin as selective senolytic candidates, while the closely related erythromycin lacked comparable activity. The study combines protein-content, real-time impedance, and metabolic analyses, providing a useful framework for drug repurposing and orthogonal senescent cell detection.

• Dual-Mode mRNA Reporters for Translational Decisions

  2026-08-13

  Translational mRNA research increasingly depends on separating delivery, intracellular fate, and functional protein expression. This thought-leadership article examines how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), combined with disciplined formulation and imaging workflows, can turn those variables into actionable development data.

• miR-24-3p, Sp1/PI3K, and Doxorubicin Heart Failure

  2026-08-12

  The reference study identifies miR-24-3p as a direct regulator of Sp1 in doxorubicin-induced heart failure, linking microRNA activity to PI3K-associated cardiomyocyte protection. Its combined rat, cell, inhibitor, gene-manipulation, and dual-luciferase design provides a useful mechanistic framework, while the model limitations caution against immediate clinical or cross-disease translation.

• EPI-001: AR N-Terminal Domain Inhibitor Workflow

  2026-08-12

  EPI-001 enables pathway-level interrogation of full-length and splice-variant androgen receptor signaling in prostate cancer and selected AR-positive TNBC models. This practical guide links N-terminal inhibition to cell-growth, transcriptional, migration, and EMT assays while addressing solubility, vehicle, and interpretation risks.

• Go 6983 and WDR36: PKC–Glycolysis Tests

  2026-08-11

  Go 6983 provides a pharmacological way to test whether PKC activity contributes to WDR36-dependent glycolysis and trophectoderm differentiation. This article translates a recent human blastoid study into a stage-aware assay framework while separating demonstrated biology from hypotheses requiring validation.

• Captopril Beyond Blood Pressure: A Translational ACE Map

  2026-08-11

  Captopril is more than a conventional ACE inhibitor: it is a mechanistically tractable probe for connecting renin–angiotensin signaling, vascular physiology, intestinal reflexes, and apoptosis-oriented oncology research. This thought-leadership guide shows how to use the compound strategically while separating established evidence from testable cross-domain hypotheses.

• N-MYC–eIF4G1 Axis in inv(16) AML

  2026-08-10

  The 2024 Science Advances study identifies an N-MYC–eIF4G1 survival program in inv(16) acute myeloid leukemia. By combining transcriptomic reanalysis, regulatory-element investigation, human leukemia models, and patient-derived xenografts, the authors connect MYCN deregulation to leukemic maintenance and define eIF4G1 as a previously unrecognized effector.

• (-)-JQ1 for Rigorous BET Control Workflows

  2026-08-09

  Use (-)-JQ1, the inactive JQ1 stereoisomer, to distinguish BET-dependent biology from vehicle, stress, and off-target effects. This practical guide connects stereochemical controls with BRD4 target gene modulation, oxidative-stress assays, and reproducible epigenetics research workflows.

• AG-221 (Enasidenib): From 2-HG to AML Dependency

  2026-08-08

  AG-221 (Enasidenib) is more than an IDH2 inhibitor: it enables a layered analysis of 2-hydroxyglutarate reduction, differentiation, and metabolic dependency. This article translates recent CD44 findings into a rigorous assay framework for acute myeloid leukemia research.

• AZ505: Selective SMYD2 Inhibitor for Reliable Assays

  2026-08-07

  Learn how AZ505, a potent and selective SMYD2 inhibitor, can improve the design and interpretation of viability, proliferation, and cytotoxicity assays. This scenario-based guide covers mechanism, compound handling, protocol optimization, renal fibrosis evidence, and practical selection of SKU B1255.

• CHIR-99021 (CT99021): Enabling Precision in Directed Stem Ce

  2026-08-07

  Explore the pivotal role of CHIR-99021 in directed stem cell differentiation, focusing on its unique mechanism and protocol innovations. Discover how this selective GSK-3 inhibitor advances both assay reliability and translational applications.

• Valemetostat (DS-3201): Advanced Epigenetic Modulation in EZ

  2026-08-06

  Explore how Valemetostat drives next-generation epigenetic cancer therapy, with a focus on its dual EZH1/EZH2 inhibition and unique clinical applications in relapsed or refractory follicular lymphoma. This in-depth review offers distinct mechanistic insights and practical assay guidance beyond standard protocol summaries.

• S-Adenosylhomocysteine: Optimizing Methylation Assays & Neur

  2026-08-06

  S-Adenosylhomocysteine (SAH) enables unmatched precision in methylation cycle and epigenetic regulation studies, facilitating both metabolic and neural differentiation workflows. This guide demystifies applied assay design, troubleshooting, and comparative advantages of APExBIO’s crystalline SAH for researchers tackling methyltransferase inhibition and homocysteine metabolism.

11628 records 1/776 page Next 12345 下5页 Last page